公开(公告)号：US20190388471A1

公开(公告)日：2019-12-26

申请号：US16435257

申请日：2019-06-07

申请人： Novartis AG ,  The Trustees of the University of Pennsylvania

发明人： Carl H. June ,  David L. Porter ,  Marcela Maus ,  Mariusz Wasik ,  Saar Gill ,  Joseph A. Fraietta ,  Marco Ruella ,  John Byrd ,  Jason Dubovsky ,  Amy Johnson ,  Natarajan Muthusamy ,  Saad Kenderian ,  Joan Mannick ,  David Jonathan Glass ,  Leon Murphy ,  Jennifer Brogdon ,  William Raj Sellers

IPC分类号： A61K35/17 ,  A61K39/395 ,  A61K31/519 ,  A61K45/06 ,  C07K14/725 ,  A61K31/436 ,  A61K31/53 ,  C12N5/0783 ,  C07K16/28

摘要： The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.

公开(公告)号：US20180140602A1

公开(公告)日：2018-05-24

申请号：US15564463

申请日：2016-04-07

申请人： Daniela Angst ,  John Byrd ,  Jason Dubovsky ,  Joseph A. Fraietta ,  Francois Gessier ,  Saar Gill ,  Amy Johnson ,  Carl H. June ,  Marcela Maus ,  Natarajan Muthusamy ,  David L. Porter ,  Marco Ruella ,  Anna Vulpetti ,  Mariusz Wasik ,  Novartis AG ,  The Trustees of the University of Pennsylvania

发明人： Daniela Angst ,  John Byrd ,  Jason Dubovsky ,  Joseph A. Fraietta ,  Francois Gessier ,  Saar Gill ,  Amy Johnson ,  Carl H. June ,  Marcela Maus ,  Natarajan Muthusamy ,  David L. Porter ,  Marco Ruella ,  Anna Vulpetti ,  Mariusz Wasik

IPC分类号： A61K31/505 ,  A61K35/17 ,  C07K16/28 ,  A61K31/506 ,  C07K16/30 ,  A61P35/00 ,  A61P35/02

CPC分类号： A61K31/505 ,  A61K31/506 ,  A61K35/17 ,  A61K45/06 ,  A61K2035/124 ,  A61K2039/505 ,  A61K2039/545 ,  A61P35/00 ,  A61P35/02 ,  C07K16/2803 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  C12N5/0636 ,  A61K2300/00

摘要： The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a BTK inhibitor, e.g., an amino pyrimidine derivative described herein. The invention also provides kits and compositions described herein.

公开(公告)号：US10357514B2

公开(公告)日：2019-07-23

申请号：US14680860

申请日：2015-04-07

申请人： The Trustees of the University of Pennsylvania ,  Novartis AG

发明人： Carl H. June ,  David L. Porter ,  Marcela Maus ,  Mariusz Wasik ,  Saar Gill ,  Joseph Fraietta ,  Marco Ruella ,  John Byrd ,  Jason Dubovsky ,  Amy Johnson ,  Natarajan Muthusamy ,  Saad Kenderian ,  Joan Mannick ,  David Glass ,  Leon Murphy ,  Jennifer Brogdon ,  William Raj Sellers

IPC分类号： A61K35/17 ,  A61K39/395 ,  A61K31/519 ,  A61K45/06 ,  C07K14/725 ,  A61K31/436 ,  A61K31/53 ,  C12N5/0783 ,  C07K16/28 ,  A61K39/00

摘要： The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.